A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
Trial details
- Registry ID
- NCT02278718
- Phase
- Phase 3
The FDA approved NexoBrid on 28 Dec 2022.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of CareNCT02278718 | MDWD | Phase 3 | Completed | 2021-04Actual |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal BurnsNCT02148705 | MDWD | Phase 3 | Completed | 2018-06-12Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-12-28Day | NexoBridMediWound Ltd · MDWD | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761192", "applicant_as_listed_by_fda": "MEDIWOUND, LTD", "brand_names": ["NEXOBRID"], "active_ingredients": ["ANACAULASE-BCDB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |